eFFECTOR Therapeutics is an early stage company focused on the discovery and development of new small molecule cancer therapeutics. eFFECTOR is developing translation regulators to selectively block disregulated translation impacting tumor growth and survival. The company has selected control of mRNA translation as a key point of theerapeutic intervention, providing potency and selectivity while inhibiting growth of cancer cells. eFFECTOR's novel approach provides a real opportunity to bring innovative new medicines to patients in need.
Osage University Partners is a venture capital fund investing in start-ups that commercialize...
Life sciences & healthcare
Mission Bay Capital, LLC, is an independent seed-stage venture firm focused on making pivotal,...
U.S. Venture Partners (USVP) is a leading Silicon valley-based venture capital firm, helping...
Corporate venture capital
11180 Roselle Street
San Diego, CA 92121